Aims: Ultra‐hypofractionated radiotherapy (UHF‐RT) is widely utilized in men with localized prostate cancer (PCa). There are limited data in Asian cohorts. We report the outcomes of a single‐arm, phase II trial of UHF‐RT from an Asian center. Methods: We recruited men with histologically confirmed, nonmetastatic localized PCa. UHF‐RT regimens were 36.25 Gy (Cohort A) and 37.5 Gy (Cohort B) delivered in five fractions every other day over 1.5–2.5 weeks. Primary endpoint was physician‐scored late genitourinary (GU) and gastrointestinal (GI) adverse events (AEs). Quality‐of‐life (QoL) was assessed by Expanded Prostate Cancer Index Composite (EPIC) at baseline, 1‐ and 2‐year post‐UHF‐RT. Results: Between March 2014 and August 2019, 105 men were recruited; four were subsequently excluded from analysis. Median age was 68.0 (Interquartile range (IQR): 63.8–73.0) years. 26 (24.8%) and 68 (64.8%) men had NCCN‐defined low‐and intermediate‐risk PCa, respectively. No late ≥G3 GU or GI toxicities were reported in both cohorts. Peak incidence of acute ≥G2 GU AEs at 14 days post‐UHF‐RT was 23.6% (17/72) and 24.0% (6/25) in Cohorts A and B, respectively; ≥G2 GI AEs were observed in 9.7% (7/72) and 36.0% (9/25), respectively. Late ≥G2 GU and GI AEs occurred in 4.7% and 3.1% of Cohort A patients, and 5.0% in Cohort B at 12 months, with no AEs at 24 months. EPIC scores changed minimally across all domains. At a median follow‐up of 44.9 months, we recorded one (1.3%) biochemical relapse by the Phoenix criteria (Cohort A). Conclusion: UHF‐RT is well tolerated in Asian men and can be a recommended fractionation schema for localized PCa. [ABSTRACT FROM AUTHOR]